Natera
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Natera sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).
Natera: 27 sponsored US clinical trials, 5 recruiting.
Natera sponsors 27 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 14 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Trisomy 13, with 3 trials.
Top-decile sponsor footprint
Natera ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
27 total, page 1 of 1
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT07214532
Sample Collection for Ongoing Research and Product Evaluation Study
NCT07318051
Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)
NCT07046585
Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection
NCT06620627
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)
NCT06808880
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
NCT06414603
LAMBDA 002 (Lung Registry) Study
NCT05170425
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
NCT05205551
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
NCT04091984
Signatera Assessment in Early-Stage Endometrial Cancer
NCT07339384
Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation
NCT05309382
Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management.
NCT05312814
Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies
NCT05004337
BESPOKE Study of ctDNA Guided Immunotherapy
NCT04761783
Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
NCT03984747
Natera Ovarian Cancer Detection Assay
NCT03485651
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
NCT02381457
High Risk Multiple Gestation Study
NCT02278874
Multiple Gestation Study
NCT02278536
Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood
NCT01852708
Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA
NCT02109770
Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing
NCT01546324
Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial
NCT01545674
Non-invasive Prenatal Diagnostic Validation Study
NCT01574781
Clinical Use of Parental Support To Detect Single Gene Mutations
NCT01197872
Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer
NCT01194531
Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)
NCT01023048
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Where Natera enrollment is open (later-stage tilt)
5 recruiting of 27 indexed (19% open); 14 completed (52%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Trisomy 13 (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Natera: open-pipeline peers nationwide
Peers matched on 27 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Natera sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 27 trials (± recruiting share)
- Akron Children's Hospital · 27 trials · 7% recruiting
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 27 trials · 0% recruiting
- AVEO Pharmaceuticals · 27 trials · 7% recruiting
- Dompé Farmaceutici S.p.A · 27 trials · 15% recruiting
Sponsors near 19% open enrollment (± trial volume)
- Florida Atlantic University · 19% recruiting · 27 trials
- Institut de Recherches Internationales Servier · 19% recruiting · 27 trials
- Nemours Children's Clinic · 19% recruiting · 108 trials
- Thomas Jefferson University · 18% recruiting · 292 trials
Related
What to do with this Natera page
27 registered trials is a research-attention snapshot, not an endorsement of Natera or any single study.
- 5 of Natera's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Trisomy 13 is the condition Natera studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Trisomy 13 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Natera pipeline card: 27 registered trials from official public datasets.Report a data error.